This program is jointly provided by Global Education and Pharmacy Times Continuing Education.
Supported by an educational grant from Otsuka America Pharmaceutical, Inc.
There is a need to educate clinicians, pharmacists and hospital policy makers in the management of hyponatremia in hospitalized patients. Continuing professional education will increase awareness of evidence-based recommendations for the diagnosis and treatment of hyponatremia. The high rate of under-diagnosis and under-treatment provides opportunities for clinicians and pharmacists to improve outcomes and the quality of care for patients with hyponatremia. To do so, they need to be familiar with diagnostic algorithms and follow clinical practice guidelines for hyponatremia. Knowledge about medical practices that reduce the risk of osmotic demyelination syndrome can help prevent over-rapid correction of hyponatremia.
Physicians, pharmacy directors, hospitalists, and health-system pharmacists
Upon completion of the activity, participants should be able to:
Distinguish new diagnostic algorithms and clinical practice guidelines for hyponatremia that can help improve the diagnosis and treatment of hospitalized patients with hyponatremia
Examine hyponatremia as a prognostic indicator in heart failure
Explore the role of vasopressin antagonists to correct hyponatremia and improve congestive symptoms in acute decompensated heart failure
Characterize the impact of hyponatremia on medical costs and pharmacoeconomic issues with vasopressin antagonists
Conflict Of Interest Disclosure Policy
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Peter L. Salgo, MD Professor of Medicine and Anesthesiology Columbia University College of Physicians and Surgeons New York, NY
Dr. Salgo has no relevant financial relationships with commercial interests to disclose.
Kiwon Lee, MD, FALP, FAHA, FCCM Director Division of Critical Care and Neurohospitalist Program Head of Neuroscience ICU Head of Neurotrauma ICU Director of Neuro Intermediate Unit Memorial Hermann Texas Medical Center Vice Chair and Associate Professor Department of Neurosurgery The University of Texas Houston Medical School Houston, TX
Dr. Lee has no relevant financial relationships with commercial interests to disclose.
Jodie L. Pepin, PharmD Director Department of Pharmacy Seton Medical Center Williamson Round Rock, Texas Assistant Clinical Professor College of Pharmacy The University of Texas at Austin Austin, TX
Dr. Pepin has no relevant financial relationships with commercial interests to disclose.
Joseph G. Verbalis, MD Professor of Medicine Chief, Endocrinology and Metabolism Georgetown University Medical Center Washington, D.C.
Dr. Verbalis has disclosed the following financial relationship with commercial interests: Consultant: Otsuka America Pharmaceutical, Inc.
Accredited Provider Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose.
Global Education Group Planning Staff—Kristen Delisi, NP, Amanda Glazar, PhD, Andrea Funk, and Laura Gilsdorf
Pharmacy Times Continuing Education Planning Staff—David Heckard and Maryjo Dixon, RPh
AMA PRA Category 1 Credit(s)TM
Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Global Education Group designates this enduring material for a maximum of 2.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Global Education Group or Pharmacy Times Continuing Education. This material is prepared based on a review of multiple sources of information, but it is not exhaustive of the subject matter.
Therefore, health care professionals and other individuals should review and consider other publications and materials on the subject.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.